Taking this into account, the identification of new conopeptides that could serve as molecular tools to study the functionality of potassium channels has been the subject of study, especially when specific subtypes are involved in the development of channelopathies such as the cases of Kv10.1 and Kv11.1, implicated in the advancement of childhood epilepsy, Temple-Baraitser syndrome [27], Zimmermann-Laband syndrome [28], tumor growth [16], and long QT syndrome [15]. Here, KCNA3 is linked to Zimmermann-Laband syndrome.